May 24, 2018 / 12:33 PM / 25 days ago

BRIEF-U.S. FDA Grants Fast Track Designation For Krystal Biotech’S Kb103

* U.S. FDA GRANTS FAST TRACK DESIGNATION FOR KRYSTAL BIOTECH’S KB103 FOR THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below